Haematology registrar at @PeterMacCC, immunologist @WEHI_Research, ex-quantum physicist and new dad
Joined July 2009
- Tweets 34
- Following 205
- Followers 104
- Likes 57
Photos and videos
Mark Dowling retweeted
5 Feb 2024
Important work regarding high prevalence of BCMA expression in PBL.
There is no consensus in the treatment of RR PBL and anti BCMA therapies are intriguing.
Interestingly the two patients exposed to CD19 directed CART in this small series died. #lymsm
3 Feb 2024
B-cell maturation antigen expression & clinical features of plasmablastic lymphoma:
- 17/18 patients w BCMA expression on IHC (94%)
- Median 75% of cells were BCMA
- 61% intermed-strong BCMA staining
onlinelibrary.wiley.com/doi/… #lymsm #mmsm
@BritSocHaem @WileyOnc_Hem @DrAEvens
4
6
1,369
Mark Dowling retweeted
27 Oct 2023
#CART and fixed #ibrutinib for #Mantle cell #lymphoma in @bloodjournal. More evidence that immunotherapy may help with high-risk molecular subtypes. Congrats to @adrianminson for driving this lightning-fast @petermacres IIT as part of his PHD! #lymsm bit.ly/3Q73904
15
55
7,891
Mark Dowling retweeted
10 Jun 2023
Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations | Blood | American Society of Hematology ashpublications.org/blood/ar…
13
31
4,418
Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:
4
87
162
96,439
Mark Dowling retweeted
5 Jun 2023
Zuma7 shows that, in spite of cross over in >50%, there is an OVERALL SURVIVAL BENEFIT for CAR-T (Axi-Cel) versus chemo transplant for #DLBCL #lymphoma - the NEJM Paper is online! bit.ly/43Fpxmn #lymsm Great to have been a part of this practice-changing trial.
19
83
9,790
Mark Dowling retweeted
23 May 2023
Surprised this went through peer-review unnoticed...
What is the issue with the proposed analysis shown in the plot?
Very exciting data nonetheless!
ncbi.nlm.nih.gov/pmc/article…
@JCO_ASCO
6
5
25
14,356
Mark Dowling retweeted
23 Jun 2022
Each year we join forces with @LLSusa & @SnowdomeAU to identify & fund new translational research projects.
Congratulations Assoc. Professor Jane Oliaro @PeterMacRes and Professor Richard Lock @KidsCancerInst!
Learn more: rebrand.ly/translational-res…
7
19
Mark Dowling retweeted
20 Jun 2022
A welcome investment in medical technology - cell and gene therapy research and therapy.
nsw.gov.au/media-releases/27…
@WestSydHealth @WestmeadInst @NSWHealth
3
6
Mark Dowling retweeted
16 Jan 2022
Physics Quiz! How many Hiroshimas/Megatons of explosive force does it take to get the Tennis off the front page of all major Australian news outlets? (Clue: it's more than 1000 Hiroshimas)
6
4
48
Mark Dowling retweeted
14 Dec 2021
Bishop - Belinda
- Tisa-cel v SOC in 2L Agg NHL
- Refract or < 12mo 1L, bridging OK
- 1 EP: EFS - death or PD/SD at 12 week assessment
- 322 random, 33% SOC had ASCT
- Median EFS both arms 3mo
- 51% crossed to tisa-cel
tisa-cel < liso/Axi - or study design issue?
#ASH21 #lymsm
5
10
31
Mark Dowling retweeted
14 Dec 2021
A fantastic opportunity to join our group @fredhutch @EvNewell1 as a Bioinformatics Analyst.
social.icims.com/viewjob/pt1…
You will help us analyze high-dimensional proteomic/genomic data from CAR T cell patients (amongst other things!)
Please RT!
@xanhira @KrishnaRJuluri
6
7
Mark Dowling retweeted
19 Sep 2021
Great review work carried out by Dr. @Razan_Mohty! 👍
19 Sep 2021
Check our paper “Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors” ⏩ @BMT J
@drjgauthier @fredhutch @MayoClinic @AUBMC_Official
Take some time to read our Tweetorial 1/9
Link to article 👉🏻rdcu.be/ctGRb
ALT Key targetable avenues to improve outcomes after CAR T-cell therapy
1
4
13
Mark Dowling retweeted
23 Aug 2021
Statement on the Doherty Institute modelling:
The Doherty Institute understands how extremely challenging lockdown restrictions are for everyone.
520
1,676
4,012
Mark Dowling retweeted
13 Jul 2021
Thrilled to see our group’s paper out. rdcu.be/cogHo Amongst the first demonstrating the potential for CRISPR-Cas13-based targeting of live SARS-CoV-2. Special congrats to the brilliant @Farehlab. Lucky to be part of this project as my first venture into basic science.
3
2
6
Mark Dowling retweeted
11 Feb 2021
Cell Therapies Pty Ltd has received TGA approval to manufacture @Novartis CAR-T therapy, Kymriah® at @PeterMacCC in Australia. This will bring faster access to treatment for eligible Australians with life-threatening blood cancers.
celltherapies.com.au/tga-app…
17
38
Mark Dowling retweeted
9 Jan 2021
Hello I am brand new to Twitter, what are you guys up to
28,227
203,525
1,523,405
Mark Dowling retweeted
30 Dec 2020
I can't help but think it should be Prof Sarah Gilbert, the actual expert overseeing the Oxford team who developed the vaccine, whose face features in these announcements.
#womeninSTEM
30 Dec 2020
It is truly fantastic news - and a triumph for British science - that the @UniofOxford /@AstraZeneca vaccine has been approved for use.
We will now move to vaccinate as many people as quickly as possible.
168
1,792
12,048